Trial Profile
An interventional, randomised, double-blind, parallel-group, placebo-controlled, active-referenced (paroxetine), fixed-dose study on the efficacy of vortioxetine on cognitive dysfunction in working patients with major depressive disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2019
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary) ; Paroxetine
- Indications Cognition disorders; Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms ReMind WORK
- Sponsors Lundbeck A/S
- 12 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2014 New trial record